Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

NCT00093080 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Leiomyosarcoma
Liposarcoma
Osteosarcoma
Sarcoma, Soft Tissue
Metastases

Interventions

DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]